Piper Sandler Maintains Overweight on Avadel Pharmaceuticals, Raises Price Target to $18
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst David Amsellem has maintained an Overweight rating on Avadel Pharmaceuticals (NASDAQ:AVDL) and raised the price target from $13 to $18.
August 10, 2023 | 7:32 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Piper Sandler has maintained an Overweight rating on Avadel Pharmaceuticals and raised the price target from $13 to $18, indicating a positive outlook for the company.
The raised price target by Piper Sandler indicates a positive outlook for Avadel Pharmaceuticals. This could lead to increased investor confidence and potentially a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100